New naloxone nasal spray at least doubles the dose

Apr 30, 2021 - 02:39 PM
FDA product update

The Food and Drug Administration today approved a naloxone hydrochloride nasal spray to treat opioid overdoses that delivers 8 milligrams of naloxone, up from 2 mg or 4 mg in previously approved products. 
 
“Addressing the opioid crisis is a top priority for the FDA, and we will continue our efforts to increase access to naloxone and place this important medicine in the hands of those who need it most,” said Patrizia Cavazzoni, M.D., director of FDA’s Center for Drug Evaluation and Research. 
 

Related News Articles

Headline
Op-ed: Nonprofit hospitals need positive margins 
An op-ed published July 9 in Modern Healthcare written by AHA President and CEO Rick Pollack and Catholic Health Association President and CEO Sr. Mary Haddad…
Headline
FDA clarifies definition of 'remanufacturing' for medical devices needing maintenance
The Food and Drug Administration May 9 released final guidance clarifying the definition of “remanufacturing” for reusable medical devices needing…
Headline
FTC issues final rule banning most noncompete clauses in employer agreements
The Federal Trade Commission April 23 voted 3-2 to issue a final rule that would ban as an unfair method of competition contractual terms that prohibit workers…
Blog
Article Misleads on Hospitals’ Charity Care Spending
A recent Modern Healthcare article misleadingly suggests that hospitals and health systems provided less charity care between 2020 and 2023. The truth is much…
Headline
FDA webinar Oct. 31 on proposed rule for laboratory developed tests 
On Oct. 31 at 1 p.m. ET, the Food and Drug Administration will host a webinar to review its recent proposed rule for laboratory developed tests,…
Perspective
Hospitals and Health Systems Advance Health for Patients and Communities in Countless Ways
All hospitals and health systems provide an oasis of care, compassion and healing to the patients and communities they serve. They offer a range of services…